TLDR
- CEO Jacob DeWitte and COO Caroline Cochran each sold ~$10M in Oklo stock on April 1, with CFO Richard Bealmear selling an additional $834K, totaling over $21M in insider sales.
- DeWitte has been selling consistently since January, offloading stock at prices ranging from ~$100 down to ~$50.
- Jim Cramer called Oklo “not a commercial enterprise” and said it has “very little prospects for making any money any time in the future.”
- Oklo missed its latest quarterly EPS estimate, reporting -$0.27 vs. the expected -$0.17.
- Analyst consensus sits at “Moderate Buy” with an average price target of $84.30, though several firms have cut their targets in recent weeks.
Three of Oklo’s top executives sold over $21 million in stock on April 1, 2026, all under pre-arranged Rule 10b5-1 trading plans.
CEO Jacob DeWitte sold stock at weighted average prices between $48.41 and $51.20 per share, totaling $10,069,852. After the sale, he directly holds 691,533 Class A shares and indirectly holds over 20 million more.
COO and co-founder Caroline Cochran also sold stock totaling $10,069,852, at prices ranging from roughly $47.99 to $51.79 per share. She directly owns 658,039 shares following the transaction.
CFO Richard Bealmear sold 16,342 shares at $51.08, bringing in $834,749. He retains 386,008 Class A shares.
All three sales were conducted under 10b5-1 plans, which are set up in advance to avoid accusations of trading on inside information.
But the April 1 sales are just part of a broader pattern for DeWitte. He has been selling Oklo stock repeatedly since January, including trades at around $112, $75, and $63 per share. In total, DeWitte has generated tens of millions in proceeds from these sales over the past few months.
The April 1 sale alone — 200,000 shares across two transactions — represented a 17.58% reduction in his direct holdings.
Cramer’s Take
The insider selling comes alongside some pointed commentary from CNBC’s Jim Cramer. When asked about Oklo on a recent episode, Cramer didn’t hold back: “Oklo, while not a science project, has very little prospects for making any money any time in the future that we think is important for a stock.”
He had made similar comments in January, calling Oklo “not a commercial enterprise” and arguing that while nuclear power has a future, companies like GE Vernova — with actual commercial operations — are better positioned than Oklo right now.
Earnings Miss and Analyst Targets
On the fundamentals side, Oklo reported a loss of $0.27 per share for its most recent quarter, missing the consensus estimate of -$0.17 by $0.10.
Analysts are still broadly bullish, but price targets have come down. UBS cut its target from $95 to $60 and rated the stock neutral. Needham dropped its target from $135 to $73, while Canaccord cut from $175 to $125. Cantor Fitzgerald held its overweight rating with a $122 target.
The average analyst price target currently sits at $84.30, with a consensus rating of “Moderate Buy.” Two analysts have a Strong Buy, nine have Buy, six have Hold, and two have Sell ratings.
Oklo’s stock has a 12-month range of $17.42 to $193.84, with the 50-day moving average at $64.62 and the 200-day at $93.16.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
